Retrophin Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
6,130.30
27,760.40
229,604.00
255,873.00
300,630.00
471,541
Total Accounts Receivable
-
7,959.40
59,307.00
65,359.00
13,872.00
14,490
Inventories
-
800.50
2,536.00
2,826.00
5,351.00
5,619
Other Current Assets
1,370.90
813.40
10,485.00
8,294.00
5,954.00
4,028
Total Current Assets
7,501.20
37,333.70
301,932.00
332,352.00
325,807.00
495,678
Net Property, Plant & Equipment
127.40
670.80
428.00
2,587.00
3,230.00
3,146
Total Investments and Advances
284.10
377.00
-
-
-
15,000
Long-Term Note Receivable
-
-
45,573.00
-
-
-
Intangible Assets
12,586.20
95,201.50
162,472.00
182,979.00
185,753.00
187,627
Other Assets
-
1,888.00
1,859.00
7,364.00
5,556.00
7,709
Total Assets
20,498.90
135,471.00
542,373.00
567,557.00
537,156.00
741,867
ST Debt & Current Portion LT Debt
-
40,485.50
-
-
-
Accounts Payable
3,553.60
7,124.30
7,639.00
7,522.00
18,938.00
Other Current Liabilities
33,011.30
59,928.80
79,342.00
75,740.00
66,730.00
Total Current Liabilities
36,564.90
107,538.60
86,981.00
83,262.00
85,668.00
Long-Term Debt
-
43,287.80
43,766.00
44,422.00
45,077.00
Provision for Risks & Charges
-
9,519.70
45,267.00
71,328.00
80,900.00
Deferred Taxes
2,600.90
141.20
24,328.00
6,425.00
-
Other Liabilities
1,000.00
12,234.50
11,951.00
12,078.00
15,567.00
Total Liabilities
40,165.80
172,721.70
242,402.00
259,790.00
244,022.00
Common Equity (Total)
19,666.90
37,250.70
299,971.00
307,767.00
293,134.00
Total Shareholders' Equity
19,666.90
37,250.70
299,971.00
307,767.00
293,134.00
Total Equity
19,666.90
37,250.70
299,971.00
307,767.00
293,134.00
Liabilities & Shareholders' Equity
20,498.90
135,471.00
542,373.00
567,557.00
537,156.00

About Retrophin

View Profile
Address
3721 Valley Centre Drive
San Diego California 92130
United States
Employees -
Website http://www.retrophin.com
Updated 07/08/2019
Retrophin, Inc. is a biopharmaceutical company, which engages in identifying, developing, and delivering therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.